Form 4: Regeneron Pharmaceuticals Director Sells Shares
Insider Transaction (Form 4)
Kathryn Guarini, a Director of Regeneron Pharmaceuticals, Inc., sold 400 shares of common stock on August 10, 2026 for $800.00 per share.
Summary
- Option exercise/conversion: acquired 400 Common Stock at $719.37 ($287,748) on August 10, 2026; holds 1,003 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $800.00 ($320,000) on August 10, 2026; holds 603 after (Direct).
- Option exercise/conversion: disposed of 400 Non-Qualified Stock Option (right to buy) on August 10, 2026; holds 1,558 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $320,000 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kathryn Guarini — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 400 | $719 | $287.7K | 1,003 |
| 2026-08-10 | Open-market sale | Common Stock | 400 | $800 | $320.0K | 603 |
| 2026-08-10 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 400 | — | — | 1,558 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (400 shares) |
| 2026-08-10 | Open-market sale (400 shares) |
| 2026-08-10 | Option exercise/conversion (400 shares) |
Keywords
insider transaction, Form 4, REGN, REGENERON PHARMACEUTICALS, INC., bearish, Kathryn Guarini
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.